Edwards Lifesciences Corp. closed 23.74% short of its 52-week high of $96.12, which the company achieved on March 28th.
3d
Hosted on MSNShould Edwards Lifesciences Stock Remain in Your Portfolio Now?Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...
Edwards Lifesciences stock fell slightly late Tuesday after the company kept its outlook for 2025 despite beating ...
A federal court granted summary judgment to Edwards Lifesciences LLC on a Title VII failure to accommodate religious observance claim of a senior cardiovascular specialist who alleged that Edwards ...
Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart ...
Edwards Lifesciences reports strong contributions from all product groups ??? TAVR, TTMT and surgical structural heart ??? in ...
On Tuesday, Edwards Lifesciences EW reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion.
Edwards Lifesciences’ EW fourth-quarter performance was backed by its most comprehensive structural heart disease portfolio. The Surgical Structural Heart business is benefiting from the strong ...
This was the stock's second consecutive day of losses.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results